Dr. Axel Ullrich, Director at the Max Planck Institute, Martinsried Chooses Proteros biostructures GmbH as Preferred Service Partner for Kinase Drug Discovery

Martinsried, Germany, February 21, 2011. Proteros Biostructures GmbH (“Proteros”) and Max Planck Institute (“MPI”) of Biochemistry, Martinsried announced today that Dr. Axel Ullrich has chosen Proteros as the preferred service partner to support kinase drug discovery research at the Department of Molecular Biology.

Proteros will develop kinase-focused assay systems and provide screening services employing its proprietary platform for screening to support the validation of novel kinase targets for drug discovery.

Dr. Axel Ullrich, co-founder of four drug discovery companies and key researcher in the development of two successfully marketed kinase drugs said that he has chosen Proteros as preferred partner for his continued drug discovery projects. Dr. Ullrich stated that he has successfully cooperated with Proteros on several projects during the past few years and is pleased with Proteros’ performance. Moreover he stated, “Proteros has proven to be a reliable and flexible partner with expertise in characterizing compound-target interactions and in the development of biochemical and cellular assay technologies.”

About Proteros:

Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery within life sciences. The company accelerates and improves protein structure analysis, kinetic and thermodynamic compound-target interaction studies and structure-guided drug discovery with its expertise, industrialized processes and unique technologies for crystallography, screening, and fragment-based lead generation. Proteros currently provides services for more than 80 pharmaceutical and biotechnology clients in Europe, North America and Japan.

About Dr. Axel Ullrich:

Dr. Ullrich is one of the leading cancer and kinase experts worldwide and among the 10 most cited scientists over the past 30 years. Dr. Ullrich is co-founder of the companies SUGEN, Axxima Pharmaceuticals, U3 Pharma and Kinaxo. His research resulted in the development of anti cancer drugs as Herceptin® and SUTENT®. Dr. Ullrich today is Director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Martinsried.


Proteros biostructures GmbH Kurt Herrenknecht, Ph.D. Am Klopferspitz 19 82152 Martinsried Germany Phone: +49 (0) 89 7007 61 – 0 P E-Mail: herrenknecht@proteros.com Internet: www.proteros.com

Dr. Axel Ullrich Max-Planck-Institute of Biochemistry Am Klopferspitz 18a 82152 Martinsried Germany Phone: +49 (0) 89 8578 2513 E-Mail: ullrich@biochem.mpg.de

Back to news